Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly
as more of these medicines near market entry.
The new strategy, “Metabolic Frontier 2030,” comes as Zealand shares have dropped 29% year to date as investors are betting the market will fragment, with fewer singular winners than they were 18 months ago at the peak of the weight loss drug frenzy.
Ahead of its Capital Markets Day on Thursday, the Danish drugmaker said it now targets five drug launches, at least 10 clinical pipeline programs and industry-leading cycle times by 2030.
The strategy will combine strategic partnerships, accelerated drug development, and expanded research capabilities to build the world’s most valuable metabolic health pipeline, Zealand Pharma said in a statement.
